SCHEMBL29890887

SCHEMBL29890887

COCCc1ccc2oc(C3CCN(c4c(C(N)=O)c(=O)n(C)c5ccccc45)CC3)nc2c1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 1/20 0.39
▸ TSHR P16473 2/20 0.37
▸ USP2 O75604 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ THRB P10828 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ SGMS2 Q8NHU3 3/20 0.36
▸ TP53 P04637 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ SGMS1 Q86VZ5 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23410934 1.00 HDAC6 (0.39) HDAC6TSHRUSP2ALDH1A1NPSR1
SCHEMBL23411359 0.94 TSHR (0.37) TSHRUSP2ALDH1A1NPSR1THRB
SCHEMBL29891532 0.94 TSHR (0.37) TSHRUSP2ALDH1A1NPSR1THRB
SCHEMBL29890336 0.87 LMNA (0.46) TSHRALDH1A1LMNATP53HSD17B10
SCHEMBL23411245 0.87 LMNA (0.46) TSHRALDH1A1LMNATP53HSD17B10
SCHEMBL23410848 0.86 TP53 (0.43) HDAC6TSHRUSP2ALDH1A1NPSR1
SCHEMBL29890670 0.86 TP53 (0.43) HDAC6TSHRUSP2ALDH1A1NPSR1
SCHEMBL23410632 0.86 NPSR1 (0.36) HDAC6TSHRUSP2ALDH1A1NPSR1
SCHEMBL29890706 0.86 NPSR1 (0.36) HDAC6TSHRUSP2ALDH1A1NPSR1
SCHEMBL23410883 0.85 LMNA (0.48) TSHRUSP2ALDH1A1NPSR1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661870-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS Bayer Aktiengesellschaft (DE) 2025-12-17 — — EP claimed
EP-4661869-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS Bayer Aktiengesellschaft (DE) 2025-12-17 — — EP claimed
CN-119523983-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-28 — — CN claimed
CN-119424429-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-14 — — CN claimed
CN-115003665-B DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2024-11-08 — — CN claimed
WO-2024165470-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2024-08-15 — — WO claimed
WO-2024165469-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS BAYER AKTIENGESELLSCHAFT (DE) 2024-08-15 — — WO claimed
EP-4065574-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2022-10-05 — — EP claimed
CN-115003665-A Substituted aminoquinolones as immunoactive DGK alpha inhibitors 拜耳公司 2022-09-02 — — CN claimed
EP-4661869-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS Bayer Aktiengesellschaft (DE) 2025-12-17 — — EP disclosed
EP-4661870-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS Bayer Aktiengesellschaft (DE) 2025-12-17 — — EP disclosed
EP-4661906-A1 COMBINATION OF CCR8 ANTIBODIES WITH DGK INHIBITORS IN THE TREATMENT OF CANCER Bayer Aktiengesellschaft (DE) 2025-12-17 — — EP disclosed
CN-119564686-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-03-07 — — CN disclosed
CN-119523983-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-28 — — CN disclosed
CN-115003665-B DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2024-11-08 — — CN disclosed
WO-2024165470-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2024-08-15 — — WO disclosed
WO-2024165468-A1 COMBINATION OF CCR8 ANTIBODIES WITH DGK INHIBITORS IN THE TREATMENT OF CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-08-15 — — WO disclosed
WO-2024165469-A1 COMBINATIONS OF DGK (DIACYLGLYCEROL KINASE) INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS AND MODULATORS BAYER AKTIENGESELLSCHAFT (DE) 2024-08-15 — — WO disclosed
EP-4065574-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2022-10-05 — — EP disclosed
CN-115003665-A Substituted aminoquinolones as immunoactive DGK alpha inhibitors 拜耳公司 2022-09-02 — — CN disclosed
Send feedback